Figure 1.
Adenovirus-mediated hAAT expression in mice treated with (A) muCTLA4Ig, n = 27; (B) muCTLA4Ig/MR1, n = 25; (C) MR1, n = 15; (D) L6, n = 16. C3H or BALB/c mice were injected with 5 × 109 plaque-forming units of Ad/RSVhAAT or Ad/PGK hAAT by tail vein on day 0. The dose of muCTLA4Ig was 200 μg on days 0, 2, and 10; the dose of MR1 was 250 μg on days 0, 2, 4, and 6; and the dose of L6 was 200 μg on days 0, 2, and 10 or 0, 2, 4, and 6. Serum samples analyzed for hAAT were tested at least in duplicate. Each line represents an individual animal.